Expiration date: 11/2026
Structure and Composition:
monocinque tablets
1 tablet contains isosorbide 5-mononitrate 40 mg
Excipients: lactose monohydrate, corn starch MCC talc magnesium stearate
in blister 15 pcs. 2 blisters in the box.
monocinque retard capsules
1 capsule contains isosorbide 5-mononitrate 50 mg
Other ingredients: sucrose, corn starch, talc, ethyl cellulose stearic acid
in blister 15 pcs. 2 blisters in the box.
Characteristic:
The organic nitrate.
Pharmachologic effect:
It acts through the formation of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP), reduction in calcium concentration in smooth muscle cells. It reduces preload (through the expansion of peripheral veins) and afterload (by reducing CSO).
Pharmacokinetics:
Once inside quickly and completely absorbed, bioavailability - 90-100%, is distributed throughout the body. Cmax in plasma attained 1-1.5 hours, T1 / 2 -. About 5 hours (8 times higher than that of isosorbide dinitrate). Excreted as metabolites mainly kidneys, about 2% - unchanged.
Description of the pharmacological actions:
Reduces myocardial oxygen demand, increasing coronary artery blood flow and improves coronary, favored partitioning into the ischemic area, reduces end-diastolic volume of the left ventricular systolic pressure and reduces its walls. It increases exercise tolerance in patients with coronary heart disease, lowers blood pressure in the pulmonary circulation.
Special Monocinque administered retard formulation with sustained release of the active substance ensures that after a single daily dose in the blood concentration provides a therapeutic effect for at least 24 hours.
Testimony:
Prevention and treatment of angina pectoris (Monocinque administered retard - III-IV functional class), rehabilitation treatment after myocardial infarction, the treatment of chronic heart failure (in combination therapy).
Contraindications:
Hypersensitivity (including to other organic nitrates), the acute phase of myocardial infarction, acute circulatory disorders (shock, collapse), hemorrhagic stroke, severe hypotension (less than 90/60 mm Hg. Art.), Concomitant use of phosphodiesterase inhibitor sildenafil (Viagra), post-traumatic brain injury, angle-closure glaucoma, children up to 18 years.
Application of pregnancy and breastfeeding:
Permissible in the case of extreme necessity, if the effect of therapy outweighs the potential risk to the fetus. At the time of treatment should stop breastfeeding.
Side effect:
Headache (early treatment with continued therapy - decreased) after the first dose - lowering blood pressure and / or the development of orthostatic hypotension (accompanied by tachycardia, dizziness, weakness). Very rarely - nausea, vomiting, facial flushing, allergic skin reactions.
Drug Interactions:
The hypotensive effect reinforce other vasodilators, antihypertensives, beta blockers, calcium channel blockers, antipsychotics, phosphodiesterase inhibitors (sildenafil), alcohol.
Dosage and administration:
Inside, after a meal, not liquid, squeezed small amounts of water.
monocinque
1 / 2-1 Table. 2 times a day, in the morning.
In the future, possible dose adjustments depending on the patient's condition.
monocinque retard
1 caps. 1 time per day in the morning.
In the future, possible dose adjustments depending on the patient's condition.
Overdose:
Treatment: induction vomiting, stomach wash, holding for hemodynamic monitoring parameters.
Precautionary measures:
To use caution in patients with glaucoma. Monocinque (tablets) are not used for the relief of angina attacks.
Special instructions:
You can use both as a monotherapy and in combination therapy with beta-blockers, calcium channel blockers, ACE inhibitors, cardiac glycosides and diuretics.
Before the drug may reduce the ability to react quickly, and therefore not recommended to drive vehicles and occupation of other potentially hazardous activities.
